Developer docs
API playgroundTry for free, no card

Search company profiles

Preceptis Medical

Full company profile

uuid0000vrx

Namestring
Preceptis Medical
Legal namestring
Preceptis Medical, Inc.
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Preceptis Medical is a privately held Minnesota-based medical device company that develops and commercializes the Hummingbird Tympanostomy Tube System (TTS), an FDA-cleared single-pass device that enables ENT surgeons to perform pediatric ear tube placement in the office without general anesthesia. Founded in 2011, the company targets the roughly 1 million pediatric ear tube procedures performed annually in the United States, a market contributing approximately $3 billion in annual healthcare costs. The device replaces the conventional OR-based surgical workflow (which can exceed $5,000 per case) with a topical-anesthetic, in-office procedure completed in under five minutes, addressing parental concerns about anesthesia, surgical scheduling constraints, and healthcare access inequities.

The Hummingbird TTS combines myringotomy incision and tube delivery into a single mechanical pass using a cutting sheath and slider, replacing the multi-step, multi-tool traditional procedure. The technology is protected by eight US patents and holds FDA 510(k) clearances (K200952 and K221254), initially approved in 2020 for children 6-24 months and expanded in August 2022 to all children 6 months and older. Clinical evidence supports a 98-99% in-office success rate, 100% tolerability with topical anesthetic, a median bilateral procedure time under five minutes, and a 97% parent recommendation rate, with no reported serious adverse events in clinical studies.

Preceptis generates revenue through direct unit sales of the Hummingbird device at under $1,000 per unit to ENT practices and hospital systems, a price point that delivers up to 65-68% cost savings versus traditional OR-based procedures. The company sells primarily via direct field sales to mid-market ENT groups and enterprise hospital systems, with channel expansion underway through a major Medicaid payer pilot (December 2023) and an AcuityMD commercial partnership (October 2025). A new CMS HCPCS add-on code G0561, effective January 1, 2025, now provides standardized reimbursement for in-office pediatric tympanostomy procedures performed with a tube delivery device. The company has raised $26 million in total investor capital, primarily from affluent individuals and a Chinese medical concern (with $1 million from Children's Minnesota), and has deliberately avoided traditional venture capital financing. The company is headquartered in Golden Valley, Minnesota, with 11-50 employees and operates exclusively in the United States.

Short descriptiontext

Preceptis Medical develops and sells the FDA-cleared Hummingbird TTS, a single-pass device that enables in-office pediatric ear tube placement without general anesthesia, marketed directly to ENT practices and hospital systems across the United States.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGolden Valley, United States
HQ citystring
Golden Valley
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pediatric ear tube devices, tympanostomy tube systems, in-office ENT procedures, minimally invasive otology, pediatric surgical instruments
Industry1 code
PRIMARYHLAHADAN
Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Pediatric Otology Medical Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Hummingbird TTS Device Sales
TypeHardware Sales
Description

Preceptis Medical generates revenue through the sale of its Hummingbird Tympanostomy Tube System medical devices to ENT practices and hospital systems. The device costs less than $1,000 per unit. Revenue is derived from direct sales to healthcare providers who perform in-office ear tube procedures.

hummingbirdeartubes.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations
Pricing details1 tier
1Hummingbird TTS Device - under $1,000 per unit
ModelUnit PricingBilling cadencePay-as-you-go
Notes

The Hummingbird device costs less than $1,000 per unit, compared to traditional OR-based ear tube surgery costs that can exceed $5,000. Cost savings of up to 65-68% compared to traditional surgical approaches.

hummingbirdeartubes.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Hummingbird TTS
Description

Hummingbird Tympanostomy Tube System - an FDA-cleared device enabling in-office pediatric ear tube placement without general anesthesia

hummingbirdeartubes.com
+2 more records
Core offering1 text field

Preceptis Medical designs, develops, and manufactures the FDA-cleared Hummingbird Tympanostomy Tube System (TTS), a single-pass medical device that allows ENT surgeons to perform pediatric ear tube placement in-office using only topical anesthesia, eliminating the need for general anesthesia and operating room procedures. The device combines myringotomy incision creation and tympanostomy tube placement into a single motion through the eardrum.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Up to 65-68% cost reduction compared to traditional OR-based ear tube surgery
+5 more records
Product overview1 text field

Preceptis Medical offers a single unified product: the Hummingbird® Tympanostomy Tube System (TTS), an FDA-cleared medical device for pediatric ear tube placement. The Hummingbird TTS is a single-pass device that enables ENT surgeons to perform ear tube insertion in their office using only topical anesthesia, eliminating the need for general anesthesia and operating room procedures. The product has evolved from its original 2020 clearance (for children 6-24 months) to an expanded 2022 labeling covering all children 6 months and older, and launched a next-generation version in 2021 with enhanced ergonomic design.

Product and service2 records
1Hummingbird Tympanostomy Tube System (TTS)
CategoryPediatric ENT Surgical Device
2Next-Generation Hummingbird Tympanostomy Tube System
CategoryPediatric ENT Surgical Device
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2025-10-21
Description

Preceptis Medical selected AcuityMD to support the expansion of its in-office pediatric ear tube device. This partnership aims to enhance the device's deployment and commercial expansion.

2Major Medicaid Payer (Pilot Program)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-12-06
Description

Collaboration with one of the largest Medicaid payers in the United States for a pilot program expanding access to Hummingbird in-office ear tube procedures for Medicaid populations. This partnership addresses healthcare access inequities and OR scheduling constraints.

hummingbirdeartubes.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Mayo Clinic was a lead clinical trial site for the Hummingbird device. Dr. Shelagh Cofer served as lead investigator and senior author of the peer-reviewed study published in Laryngoscope Investigative Otolaryngology.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

HealthPartners was among the early ordering customers for the Hummingbird device and participated in the commercial pilot program.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dr. Ted Truitt of St. Cloud ENT was the primary author and one of the lead investigators for the clinical trial. St. Cloud ENT was among the first practices to order the Hummingbird device.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Phoenix Children's Hospital was one of the first hospitals in the nation to use the Hummingbird device. Dr. Nathan Page worked with Mayo Clinic to bring the device to Arizona.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Children's Hospital Colorado began offering the Hummingbird procedure as one of the first patients to receive ear tubes with the device at the hospital.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Cedars-Sinai was one of the initial eight institutions across the country involved in clinical trials of the Hummingbird device.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Dr. Paula Harmon of PENTA participated in the Medicaid insurer pilot program and was voted a Top ENT Doctor in a national listing in 2022.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Large diversified medical device and surgical instruments manufacturer. Comparable as a broad surgical/medical device incumbent with overlapping sales channels into ENT and pediatric OR settings.

TypeBroad incumbent
Description

Manufacturer of ENT endoscopes and surgical instruments, with deep presence in ENT offices and ORs. Adjacent competitor in the ENT surgical device category.

TypeDirect peer
Description

Smith+Nephew acquired Tusker Medical, which was developing a competing in-office pediatric tympanostomy tube delivery system (Tula). Most directly comparable peer as a same-category, same-indication, in-office ear tube competitor.

TypeBroad incumbent
Description

Medtronic manufactures traditional tympanostomy/ear tubes and broader ENT surgical products. Incumbent with existing hospital relationships; would likely be a partner, acquirer, or direct competitor in pediatric ENT.

5Johnson & Johnson (Acclarent)
TypeBroad incumbent
Description

Acclarent (J&J) is a leader in ENT intervention devices (e.g., balloon sinuplasty). Broad incumbent in ENT with the commercial scale and ENT relationships to either develop or distribute competing in-office pediatric products.

6Cook Medical
TypeDirect peer
Description

Cook Medical manufactures tympanostomy (ear) tubes and other ENT products. Directly comparable as an established ear tube manufacturer supplying the same clinical workflow.

TypeDirect peer
Description

Specialty manufacturer of ENT surgical products including tympanostomy tubes and middle-ear prostheses. Directly comparable as a focused ear-tube and middle-ear surgical product competitor.

TypeBroad incumbent
Description

Global manufacturer of endoscopes and ENT surgical instruments used in ear tube procedures. Broad incumbent in ENT visualization and instrumentation.

TypeEmerging player
Description

ENT-focused device company (acquired by Medtronic) specializing in office-based sinuplasty products. Comparable as a focused ENT device company that drove the shift from OR to office procedures in a parallel category.

TypeOthers
Description

Medical device commercial-intelligence platform announced as Preceptis' GTM partner in October 2025. Comparable as a commercial-enablement partner serving the med-device go-to-market motion.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Preceptis Medical

Pediatric Otology Medical Deviceshummingbirdeartubes.com

Preceptis Medical develops and sells the FDA-cleared Hummingbird TTS, a single-pass device that enables in-office pediatric ear tube placement without general anesthesia, marketed directly to ENT practices and hospital systems across the United States.

What Preceptis Medical does

Preceptis Medical is a privately held Minnesota-based medical device company that develops and commercializes the Hummingbird Tympanostomy Tube System (TTS), an FDA-cleared single-pass device that enables ENT surgeons to perform pediatric ear tube placement in the office without general anesthesia. Founded in 2011, the company targets the roughly 1 million pediatric ear tube procedures performed annually in the United States, a market contributing approximately $3 billion in annual healthcare costs. The device replaces the conventional OR-based surgical workflow (which can exceed $5,000 per case) with a topical-anesthetic, in-office procedure completed in under five minutes, addressing parental concerns about anesthesia, surgical scheduling constraints, and healthcare access inequities.

The Hummingbird TTS combines myringotomy incision and tube delivery into a single mechanical pass using a cutting sheath and slider, replacing the multi-step, multi-tool traditional procedure. The technology is protected by eight US patents and holds FDA 510(k) clearances (K200952 and K221254), initially approved in 2020 for children 6-24 months and expanded in August 2022 to all children 6 months and older. Clinical evidence supports a 98-99% in-office success rate, 100% tolerability with topical anesthetic, a median bilateral procedure time under five minutes, and a 97% parent recommendation rate, with no reported serious adverse events in clinical studies.

Preceptis generates revenue through direct unit sales of the Hummingbird device at under $1,000 per unit to ENT practices and hospital systems, a price point that delivers up to 65-68% cost savings versus traditional OR-based procedures. The company sells primarily via direct field sales to mid-market ENT groups and enterprise hospital systems, with channel expansion underway through a major Medicaid payer pilot (December 2023) and an AcuityMD commercial partnership (October 2025). A new CMS HCPCS add-on code G0561, effective January 1, 2025, now provides standardized reimbursement for in-office pediatric tympanostomy procedures performed with a tube delivery device. The company has raised $26 million in total investor capital, primarily from affluent individuals and a Chinese medical concern (with $1 million from Children's Minnesota), and has deliberately avoided traditional venture capital financing. The company is headquartered in Golden Valley, Minnesota, with 11-50 employees and operates exclusively in the United States.

Preceptis Medical firmographics

Firmographics
Name
Preceptis Medical
Legal name
Preceptis Medical, Inc.
Website
https://hummingbirdeartubes.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
Preceptis Medical develops and sells the FDA-cleared Hummingbird TTS, a single-pass device that enables in-office pediatric ear tube placement without general anesthesia, marketed directly to ENT practices and hospital systems across the United States.
Ownership category
akta.pro rank

Preceptis Medical industry classification

Industry
Product category
Pediatric Otology Medical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHADAN
Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment

Keywords

  • Pediatric ear tube devices
  • Tympanostomy tube systems
  • In-office ENT procedures
  • Minimally invasive otology
  • Pediatric surgical instruments

Where Preceptis Medical is headquartered

Location

Headquarters

HQ city
Golden Valley
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Preceptis Medical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations

Revenue model

  1. Hummingbird TTS Device Sales: Preceptis Medical generates revenue through the sale of its Hummingbird Tympanostomy Tube System medical devices to ENT practices and hospital systems. The device costs less than $1,000 per unit. Revenue is derived from direct sales to healthcare providers who perform in-office ear tube procedures.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goHummingbird TTS Device - under $1,000 per unit

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Preceptis Medical product offering

Product offering

Core offering

Preceptis Medical designs, develops, and manufactures the FDA-cleared Hummingbird Tympanostomy Tube System (TTS), a single-pass medical device that allows ENT surgeons to perform pediatric ear tube placement in-office using only topical anesthesia, eliminating the need for general anesthesia and operating room procedures. The device combines myringotomy incision creation and tympanostomy tube placement into a single motion through the eardrum.

Product overview

Preceptis Medical offers a single unified product: the Hummingbird® Tympanostomy Tube System (TTS), an FDA-cleared medical device for pediatric ear tube placement. The Hummingbird TTS is a single-pass device that enables ENT surgeons to perform ear tube insertion in their office using only topical anesthesia, eliminating the need for general anesthesia and operating room procedures. The product has evolved from its original 2020 clearance (for children 6-24 months) to an expanded 2022 labeling covering all children 6 months and older, and launched a next-generation version in 2021 with enhanced ergonomic design.

Differentiator

Problem solved

Functional benefit

Brands

  • Hummingbird TTS: Hummingbird Tympanostomy Tube System - an FDA-cleared device enabling in-office pediatric ear tube placement without general anesthesia
  • Hummingbird Procedure
  • One-Pass Technology

Products and services

  • Hummingbird Tympanostomy Tube System (TTS)
  • Next-Generation Hummingbird Tympanostomy Tube System

Quantifiable outcome

  • Up to 65-68% cost reduction compared to traditional OR-based ear tube surgery
  • +5 more outcomes

Companies that use Preceptis Medical

Customer profile

Named customers7 records

Segments2 records

Ideal customer profiles2 records

Preceptis Medical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Preceptis Medical partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and minor.

  • AcuityMDcoreGTM or Marketing Partner · 21 October 2025Preceptis Medical selected AcuityMD to support the expansion of its in-office pediatric ear tube device. This partnership aims to enhance the device's deployment and commercial expansion.
  • Major Medicaid Payer (Pilot Program)coreStrategic or Co-development Partner · 6 December 2023Collaboration with one of the largest Medicaid payers in the United States for a pilot program expanding access to Hummingbird in-office ear tube procedures for Medicaid populations. This partnership addresses healthcare access inequities and OR scheduling constraints.
  • Mayo CliniccoreStrategic or Co-development PartnerMayo Clinic was a lead clinical trial site for the Hummingbird device. Dr. Shelagh Cofer served as lead investigator and senior author of the peer-reviewed study published in Laryngoscope Investigative Otolaryngology.
  • HealthPartnersminorStrategic or Co-development PartnerHealthPartners was among the early ordering customers for the Hummingbird device and participated in the commercial pilot program.
  • St. Cloud Ear, Nose & ThroatcoreStrategic or Co-development PartnerDr. Ted Truitt of St. Cloud ENT was the primary author and one of the lead investigators for the clinical trial. St. Cloud ENT was among the first practices to order the Hummingbird device.
  • Phoenix Children's HospitalminorStrategic or Co-development PartnerPhoenix Children's Hospital was one of the first hospitals in the nation to use the Hummingbird device. Dr. Nathan Page worked with Mayo Clinic to bring the device to Arizona.
  • Children's Hospital ColoradominorStrategic or Co-development PartnerChildren's Hospital Colorado began offering the Hummingbird procedure as one of the first patients to receive ear tubes with the device at the hospital.
  • Cedars-SinaiminorStrategic or Co-development PartnerCedars-Sinai was one of the initial eight institutions across the country involved in clinical trials of the Hummingbird device.
  • PENTA (Pediatric Ear, Nose & Throat of Atlanta)minorStrategic or Co-development PartnerDr. Paula Harmon of PENTA participated in the Medicaid insurer pilot program and was voted a Top ENT Doctor in a national listing in 2022.

Scale indicators7 records

Recent moves5 records

Expansion highlights5 records

Preceptis Medical competitors and assessment

Company assessment

Broad incumbents

  • Stryker: Large diversified medical device and surgical instruments manufacturer. Comparable as a broad surgical/medical device incumbent with overlapping sales channels into ENT and pediatric OR settings.
  • Olympus Corporation: Manufacturer of ENT endoscopes and surgical instruments, with deep presence in ENT offices and ORs. Adjacent competitor in the ENT surgical device category.
  • Medtronic: Medtronic manufactures traditional tympanostomy/ear tubes and broader ENT surgical products. Incumbent with existing hospital relationships; would likely be a partner, acquirer, or direct competitor in pediatric ENT.
  • Johnson & Johnson (Acclarent): Acclarent (J&J) is a leader in ENT intervention devices (e.g., balloon sinuplasty). Broad incumbent in ENT with the commercial scale and ENT relationships to either develop or distribute competing in-office pediatric products.
  • KARL STORZ: Global manufacturer of endoscopes and ENT surgical instruments used in ear tube procedures. Broad incumbent in ENT visualization and instrumentation.

Direct peers

  • Smith+Nephew (Tusker Medical): Smith+Nephew acquired Tusker Medical, which was developing a competing in-office pediatric tympanostomy tube delivery system (Tula). Most directly comparable peer as a same-category, same-indication, in-office ear tube competitor.
  • Cook Medical: Cook Medical manufactures tympanostomy (ear) tubes and other ENT products. Directly comparable as an established ear tube manufacturer supplying the same clinical workflow.
  • Grace Medical: Specialty manufacturer of ENT surgical products including tympanostomy tubes and middle-ear prostheses. Directly comparable as a focused ear-tube and middle-ear surgical product competitor.

Emerging players

  • Intersect ENT: ENT-focused device company (acquired by Medtronic) specializing in office-based sinuplasty products. Comparable as a focused ENT device company that drove the shift from OR to office procedures in a parallel category.

Others

  • AcuityMD: Medical device commercial-intelligence platform announced as Preceptis' GTM partner in October 2025. Comparable as a commercial-enablement partner serving the med-device go-to-market motion.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Preceptis Medical social profiles

Digital presence

Preceptis Medical compliance and trust

Trust signal

Compliance1 record

Preceptis Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Preceptis Medical leadership team

Management profile

Number of profiles

Profiles10 records

Preceptis Medical funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Preceptis Medical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Preceptis Medical

What does Preceptis Medical do?

Preceptis Medical designs, develops, and manufactures the FDA-cleared Hummingbird Tympanostomy Tube System (TTS), a single-pass medical device that allows ENT surgeons to perform pediatric ear tube placement in-office using only topical anesthesia, eliminating the need for general anesthesia and operating room procedures. The device combines myringotomy incision creation and tympanostomy tube placement into a single motion through the eardrum.

Is Preceptis Medical a public or private company?

Preceptis Medical is a private company. It is classified as venture growth investor backed and is currently operating.

When was Preceptis Medical founded?

Preceptis Medical was founded in 2011. It employs 11 to 50 people.

Where is Preceptis Medical based?

Preceptis Medical is headquartered in Golden Valley, United States, in the North America region.

How does Preceptis Medical make money?

One revenue line is on record: hummingbird TTS Device Sales.

Who are Preceptis Medical's main competitors?

Broad incumbents on record are Stryker, Olympus Corporation, Medtronic, Johnson & Johnson (Acclarent) and KARL STORZ. Direct peers are Smith+Nephew (Tusker Medical), Cook Medical and Grace Medical. Intersect ENT is listed as an emerging player. AcuityMD is listed as an others.

Does Preceptis Medical have an API?

No public API is recorded for Preceptis Medical.

What industry is Preceptis Medical in?

Preceptis Medical's product category is Pediatric Otology Medical Devices. Its primary akta.pro industry code is HLAHADAN, Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Contemporary PediatricsHummingbird TTS ear tube system expanded for use in young childrenPreceptis Medical received FDA clearance to expand the use of its Hummingbird Tympanostomy Tube System (TTS) for children aged 6 months and above. This regulatory approval allows otolaryngologists to perform ear tube procedures in an office setting without general anesthesia or an operating room, potentially saving costs for approximately one million annual pediatric patients.BioWorldFDA upgrades label for Preceptis tympanostomy deviceThe U.S. FDA granted Preceptis Inc. expanded clearance for its Hummingbird Tympanostomy Tube System, extending eligibility for office-based pediatric ear tube procedures to all children six months and older. This regulatory update removes the previous age restriction of 6-24 months, allowing the minimally invasive device to be used without general anesthesia in a broader patient demographic.MassDevicePreceptis Medical has a new CEO as it advances ear tube techPreceptis Medical has appointed Dave Carey as its new CEO to lead the company's next phase of growth ahead of the full release of its Hummingbird Tympanostomy Tube System. Carey, formerly the chief commercial officer at Pristine Surgical, will oversee the commercialization of the FDA-cleared device which allows for in-office ear tube placement without general anesthesia.MassDevicePreceptis Medical ArchivesPreceptis Medical has appointed Dave Carey as its new CEO ahead of the release of its Hummingbird Tympanostomy Tube System. The FDA has granted expanded indications for this system, allowing for in-office procedures for children aged 6 months and older, significantly reducing trauma and procedure time. This development marks a strategic advancement in pediatric ear tube placement technology for the company.Business Wire BlogPreceptis Medical Appoints Dave Carey as Chief Executive Officer to Lead Next Phase of Strategic GrowthPreceptis Medical, Inc. appointed Dave Carey as its new Chief Executive Officer to lead the company's next phase of strategic growth and market expansion. Carey will oversee the continued U.S. rollout of the Hummingbird Tympanostomy Tube System, a device designed for in-office pediatric ear tube placement without general anesthesia. This leadership change coincides with the company's efforts to accelerate the commercial release of its flagship product.MayoclinicIn-office, ear tube procedure reduces stress and adverse effectsMayo Clinic Children's Center is utilizing the FDA-approved Hummingbird Tympanostomy Tube System to perform ear tube procedures in-office, reducing the need for general anesthesia. Preceptis Medical funded the clinical research for this device, which allows for faster placement and lower costs compared to traditional operating room methods. The procedure aims to reduce stress and adverse effects like emergence delirium for pediatric patients.Daily Medical NewsFDA clears ear tube device for all children aged 6 months or olderThe FDA has cleared Preceptis Medical’s Hummingbird Tympanostomy Tube System for use in children aged 6 months and older, expanding its previous indication to include infants. This approval allows otolaryngologists to perform ear tube procedures in-office using topical anesthesia, eliminating the need for general anesthetic and operating room settings. The expansion aims to reduce medical costs and patient trauma for the approximately 1 million annual ear tube procedures performed in the United States.MassDeviceFDA clears expanded labeling for Preceptis Medical’s ear tube systemThe FDA has cleared expanded labeling for Preceptis Medical’s Hummingbird tympanostomy tube system, allowing its use in children aged 6 months and older for office-based procedures. This expansion increases the eligible patient population from the previous limit of 24 months, potentially shifting millions of annual ear tube procedures from operating rooms to clinical settings. Preceptis plans to leverage this regulatory approval to support a larger commercial launch and expand access to the device.https://www.azfamily.comPhoenix Children’s first in state to use new ear tube placement devicePhoenix Children’s Hospital has become the first in Arizona to implement the Hummingbird device, a new tool created by Preceptis Medical that simplifies ear tube placement. This technology allows for quicker procedures without anesthesia, significantly reducing patient recovery time and clinical complexity compared to traditional methods.Daily Medical NewsOffice-based tympanostomy tube placement: A safe and efficient alternativeThe article reviews office-based tympanostomy tube placement as a safe and efficient alternative to operating room procedures, highlighting two FDA-approved commercial systems: Tula by Tusker Medical and Hummingbird by Preceptis Medical. Clinical studies indicate high success rates for these in-office procedures using local anesthesia, which reduce healthcare costs and avoid the risks associated with general anesthesia in children. The American Academy of Otolaryngology-Head and Neck Surgery supports this approach for carefully selected patients through shared decision-making.